Opko Health (NASDAQ:OPK) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Thursday.
Several other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $13.34.
Shares of Opko Health (OPK) traded down $0.21 during midday trading on Thursday, reaching $3.18. 7,293,981 shares of the company traded hands, compared to its average volume of 5,210,000. The firm has a market cap of $1,780.00, a P/E ratio of -16.74 and a beta of 1.42. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health has a 1-year low of $3.16 and a 1-year high of $8.64.
Institutional investors have recently added to or reduced their stakes in the business. Ellington Management Group LLC acquired a new position in Opko Health during the 4th quarter valued at about $112,000. Crossmark Global Holdings Inc. acquired a new position in Opko Health during the 3rd quarter valued at about $118,000. State of Alaska Department of Revenue acquired a new position in Opko Health during the 4th quarter valued at about $144,000. The Manufacturers Life Insurance Company lifted its position in Opko Health by 7.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 1,657 shares during the period. Finally, First Trust Advisors LP acquired a new position in Opko Health during the 4th quarter valued at about $154,000. Institutional investors own 22.22% of the company’s stock.
About Opko Health
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.